Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate gene transcription in response to peroxisome proliferators and fatty acids. PPARs also play an important role in the regulation of adipocyte differentiation. It is unclear, however, what naturally occurring compounds activate each of the PPAR subtypes. To address this issue, a screening assay was established using heterologous fusions of the bacterial tetracycline repressor to several members of the peroxisome proliferator-activated receptor (PPAR) family. This assay was employed to compare the activation of PPAR family members by known PPAR activators including peroxisome proliferators and fatty acids. Interestingly, the activation of PPARs by fatty acids was partially inhibited by the cyclooxygenase inhibitor indomethacin, which prevents prostaglandin synthesis. Indeed, prostaglandins PGA1 and 2, PGD1 and 2, and PGJ2-activated PPARs, while a number of other prostaglandins had no effect. We also screened a variety of hydroxyeicosatetraenoic acids (HETEs) for the ability to activate PPARs. 8(S)-HETE, but not other (S)-HETEs, was a strong activator of PPAR␣. Remarkably, PPAR activation by 8(S)-HETE was stereoselective. In addition, 8(S)-HETE was able to induce differentiation of 3T3-L1 preadipocytes. These results indicate that PPARs are differentially activated by naturally occurring eicosanoids and related molecules.The cloning and characterization of nuclear receptors has greatly enhanced our understanding of gene regulation by lipophilic hormones such as steroids, vitamin D, thyroxine, and retinoids. These receptors comprise a superfamily of transcription factors containing highly related DNA-binding domains (1, 2). This family includes multiple subtypes of receptors for thyroxine and retinoids, encoded by distinct genes which are regulated quite differently during development and in the adult.

Ras proteins are signal transducers for many cellular responses. However, it is not well established whether Rassignaling also contributes to apoptosis. We have constructed H-Ras R12 -transformed Rat1 fibroblasts using tetracycline operator/repressor (TetO/TetR)-based conditional vectors. Rat1/TetO-Ras R12 (Rat1-Ras) cells produced high levels of HRas R12 protein and exhibited oncogenic transformation. Treatment of Rat1-Ras cells with 0.1% serum triggered massive apoptosis. Rat1-Ras cells expressed increased basal activities of extracellular response kinase (ERK) and p46/p54 stress-activated protein kinase/c-Jun NH 2 -terminal kinase (SAPK/JNK). Interestingly, Ras-dependent apoptosis correlated with further persistent activation of both p46 and p54 SAPK/JNK and concurrent inhibition of ERK. Differential modulation of SAPK/JNK and ERK was not detected in tetracycline-treated cells that did not commit apoptosis. Furthermore, two Bcl-x related proteins of 15 kDa and 18 kDa were highly induced in apoptotic Rat1-Ras cells. Our results establish a direct role for Ras in apoptosis, and suggest a functional relationship between H-Ras, SAPK/JNK, ERK and Bcl-x in regulating apoptosis.

N-Methylnitrosourea (NMU)-induced codon 12 Ki-ras mutations were analyzed in premalignant thymic lymphomas from C57BL/6J mice by using a selective polymerase chain reaction amplification strategy. The frequency of codon 12 Ki-ras mutations was 67% (16 of 24) in NMU-treated animals with premalignant stage I disease. Previously, animals with different stages of disease had been analyzed for cytogenetic changes and for mutations in the p53 tumor suppressor gene. The genetic changes observed were early-activating codon 12 G35-->A transition mutations of the Ki-ras gene, followed closely by trisomy 15 and infrequent mutation of the p53 gene late in tumor development. The consistent and early detection of Ki-ras mutations in NMU-treated animals but not in untreated controls suggests that the mutations result from direct carcinogen exposure. Alternate pathways of NMU-induced thymic lymphomagenesis were implicated. One pathway involved putative NMU-induced mutations in other, non-ras oncogenes that cooperate with trisomy 15 to produce similar T-cell tumors. The frequency of p53 gene mutations in human and murine T-cell tumors is similar but low.

No abstract

Background. Risk factors for stroke have been extensively studied, however, few studies have been carried out in high-altitude cities. Objectives. To evaluate the difference in blood viscosity, using direct methods, in stroke patients versus patients without stroke to discover any possible association. Design and setting. A cross-sectional study was carried out in the city of Cusco, Peru (3399 m.a.s.l). Methods: Participants included stroke patients with less than three days of illness and controls without stroke. Viscosity levels were measured in all patients using a cone-plate viscometer. Blood viscosity was evaluated at 10, 20, 30 and 40 revolutions per minute (RPM) because blood is considered a nonNewtonian fluid. Plasma viscosity was evaluated at 100RPM. All viscosity units are expressed as means standard deviations (SD) in centipoises (cP). Results: A total of 204 patients were included (61 cases/143 controls). The mean age was 67.5 (SD:15.9), and 88 (43%) were women. The means of blood viscosity for 10, 20, 30RPM in the stroke cases were 5.85cP (SD:1.21), 5.22cP (SD:1.09), and 4.91cP (SD:1.02), and 4.81cP (SD:1.02) respectively. For the controls were of 5.57cP (SD:1.19), 4.89cP (SD:4.85), 4.63cP (SD:0.97), 4.56cP (SD:0.95), respectively. All measured means were tested with significant differences (p <0.01). Plasma viscosities were 1.43cP (SD:0.17) for the stroke cases and 1.49cP (SD:0.23) for controls (p=0.05). Conclusions: This study found that blood viscosity is 0.3cP higher in stroke patients. This suggests that blood viscosity could play a role in the etiology. The results presented are preliminary and the study is still under development.